Journal of Neural Transmission

, Volume 117, Issue 12, pp 1395–1399 | Cite as

Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease

  • Nir Giladi
  • Andreas Fichtner
  • Werner Poewe
  • Babak Boroojerdi
Movement Disorders - Short Communication


This open-label study (NCT00243945) investigated the efficacy of rotigotine transdermal system in 54 Parkinson’s disease (PD) patients with unsatisfactory control of early morning motor impairment and sleep disturbances. Rotigotine dose was up titrated for 8 weeks and maintained for 4 weeks. Mean rotigotine dose at end of maintenance was 11.83 mg/24 h (SD 3.86). Patients had two overnight hospital stays at baseline and end of treatment during which early morning motor performance was assessed, prior to first morning dose of regular oral antiparkinsonian medication. Rotigotine improved mean Unified Parkinson’s Disease Rating Scale (UPDRS) part III score by −9.3 points, mean Timed Up and Go test duration by −1.4 s and mean morning finger tapping by 26.5 taps/min; 46% of patients were considered responders (≥30% improvement of UPDRS III). Mean Nocturnal Akinesia, Dystonia and Cramps Sum Score was reduced by 61%; mean number of nocturias decreased by 32%. Rotigotine also improved sleep quality. These results suggest a role for rotigotine in treatment of nocturnal and early morning motor disabilities in PD patients.


Dopamine agonist Early morning akinesia Parkinson’s disease Rotigotine transdermal patch Sleep disorders 



The authors would like to thank all SP826 investigators for their contributions (study conception and design, data collection, and providing and caring for study patients). The authors also thank Dr. E. Grosselindemann and Dr. B. Brett (Brett Medical Writing) for providing medical writing services and editorial assistance, Dr. H. C. Carney (Evidence Scientific Solutions) for editorial assistance, and Ms. G.-G. Li (Global Publications Manager, Movement and Sleep Disorders, UCB Pharma SA) for publication coordination. The study was sponsored by Schwarz Biosciences GmbH, a member of the UCB Group of Companies, delegated by Schwarz Pharma Ltd, Ireland. The sponsor was involved in study design, data analysis and interpretation, report writing, and the decision to submit the paper for publication. The sponsor also undertook all costs associated with the development and the publishing of the present manuscript.

Conflicts of interest

AF and BB are employees of the study sponsor. NG received honoraria for consultancy from the sponsor as part of the International Advisory Board of UCB in regards to Parkinson’s disease. He received no compensation for any work in relation to this paper or this study. WP received honoraria for consultancy and lecture fees from the study sponsor.


  1. Abdelgabar A, Sharma J (2003) Sleep disorders in Parkinson’s disease. Int J Clin Pract 57:781–787PubMedGoogle Scholar
  2. Aranda B, Cramer P (1993) Effect of apomorphine and l-dopa on the parkinsonian bladder. Neurourol Urodyn 12(3):203–209CrossRefPubMedGoogle Scholar
  3. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 20:224–230CrossRefPubMedGoogle Scholar
  4. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 55:1–9CrossRefPubMedGoogle Scholar
  5. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Hogl B, Trenkwalder C (2002) The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:629–635CrossRefPubMedGoogle Scholar
  6. Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. MacMillan Healthcare Information, Florham Park, pp 153–163Google Scholar
  7. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH (2007) Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398–2404CrossRefPubMedGoogle Scholar
  8. Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Herzog H, Volkmann J, Deuschl G, Fink GR (2006) Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain 129:3366–3375CrossRefPubMedGoogle Scholar
  9. Högl B, Rothdach A, Wetter TC, Trenkwalder C (2003) The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology 28:1866–1870CrossRefPubMedGoogle Scholar
  10. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMedGoogle Scholar
  11. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, Watts R (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7:2–13CrossRefPubMedGoogle Scholar
  12. Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 11:512–519CrossRefPubMedGoogle Scholar
  13. Morris S, Morris ME, Lansek R (2001) Reliability of measurements obtained with the Timed “Up & Go” test in people with Parkinson disease. Phys Ther 81:810–818PubMedGoogle Scholar
  14. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513–520CrossRefPubMedGoogle Scholar
  15. Pressman MR, Figueroa WG, Kendrick-Mohamed J, Greenspon LW, Peterson DD (1996) Nocturia. A rarely recognized symptom of sleep apnea and other occult sleep disorders. Arch Intern Med 156(5):545–550CrossRefPubMedGoogle Scholar
  16. Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 100:163–167CrossRefPubMedGoogle Scholar
  17. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S (1998) Sleep disorders in Parkinson’s disease. J Neurol 245:S15–S18CrossRefPubMedGoogle Scholar
  18. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, RECOVER study group (2010) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (in press)Google Scholar
  19. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272–276CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Nir Giladi
    • 1
  • Andreas Fichtner
    • 2
  • Werner Poewe
    • 3
  • Babak Boroojerdi
    • 2
  1. 1.Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Schwarz Biosciences GmbH, a member of the UCB Group of CompaniesMonheimGermany
  3. 3.Department of NeurologyInnsbruck Medical UniversityInnsbruckAustria

Personalised recommendations